|
|
|
|
|
Estramustine
drug data and news
Estramustine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Estramustine | ||
| Brand Names/Synonyms | Emcyt; Estracyt; Estramustin Sodium Phosphate; Estramustina [Inn-Spanish]; Estramustine; Estramustine Sodium Phosphate; Estramustine [Usan:Ban:Inn]; Estramustinum [Inn-Latin]; Leo 275 | ||
| Indication | For the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Estramustine is an antineoplastic agent indicated in the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate. Estramustine is a combination of estradiol with nornitrogen mustard. The precise mechanism of action of estramustine is unknown. Unlike other alkylating agents, estramustine does not directly damage DNA. | ||
| Mechanism Of Action | The precise mechanism of action of estramustine is unknown. | ||
| Estramustine News (When available) |
Positive Findings From Clinical Studies of QUADRAMET(R) in ... Feb 27, 2006 Positive Findings from Clinical Studies of Quadramet in Prostate ... Feb 27, 2006 Positive Findings from Clinical Studies of QUADRAMET in Prostate ... Feb 27, 2006 | ||
| Dosage Forms | CAPSULE | ||
| Drug_Category | Antineoplastic Agents; Antineoplastic Agents; Radiation-Protective Agents; ATC:L01XX11 | ||
| Absorption | Not Available | ||
| Interactions |
Interactions for Estramustine: Milk, milk products, and calcium-rich foods or drugs may impair the absorption of EMCYT. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | (17-hydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl)bis(2-chloroethyl)aminomethanoate | ||
| Chemical Formula | C23H31Cl2NO3 | ||
| Molecular Weight | 440.403 g/mol | ||
| Smiles String | CC12CCC3C(C1CCC2O)CCC4=C3C=CC(=C4)OC(=O)N(CCCl)CCCl | ||
| Melting Point | 104.5 °C | ||
| Water Solubility | Not Available | ||
| State | Solid | ||
| LogP/Hphobicity | 4.636 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not Available | ||
| Half Life | 20 hours | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Estramustine.html http://www.rxlist.com/cgi/generic2/estramustine.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00625 | ||
| CAS Registry Number | 2998-57-4 | ||
| KEGG Compound ID | C11228 | ||
| PubChem ID | SID:161211 | ||
| PharmGKB ID | Not Available | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2063794 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |